The advent of evidence based medicine was a paradigm shift intended to provide a solid scientific foundation for medicine. The validity of this new paradigm, however, depends on reliable data from clinical trials, most of which are conducted by the pharmaceutical industry and reported in the names of senior academics. The release into the public domain of previously confidential pharmaceutical industry documents has given the medical community valuable insight into the degree to which industry sponsored clinical trials are misrepresented.1234 Until this problem is corrected, evidence based medicine will remain an illusion.
The philosophy of critical rationalism, advanced by the philosopher Karl Popper, famously advocated for the integrity of science and its role in an open, democratic society. A science of real integrity would be one in which practitioners are careful not to cling to cherished hypotheses and take seriously the outcome of the most stringent experiments.5 This ideal is, however, threatened by corporations, in which financial interests trump the common good. Medicine is largely dominated by a small number of very large pharmaceutical companies that compete for market share, but are effectively united in their efforts to expanding that market. The short term stimulus to biomedical research because of privatisation has been celebrated by free market champions, but the unintended, long term consequences for medicine have been severe. Scientific progress is thwarted by the ownership of data and knowledge because industry suppresses negative trial results, fails to report adverse events, and does not share raw data with the academic research community. Patients die because of the adverse impact of commercial interests on the research agenda, universities, and regulators.
The pharmaceutical industry’s responsibility to its shareholders means that priority must be given to their hierarchical power structures, product loyalty, and public relations propaganda over scientific integrity. Although universities have always been elite institutions prone to influence through endowments, they have long laid claim to being guardians of truth and the moral conscience of society. But in the face of inadequate government funding, they have adopted a neo-liberal market approach, actively seeking pharmaceutical funding on commercial terms. As a result, university departments become instruments of industry: through company control of the research agenda and ghostwriting of medical journal articles and continuing medical education, academics become agents for the promotion of commercial products.6 When scandals involving industry-academe partnership are exposed in the mainstream media, trust in academic institutions is weakened and the vision of an open society is betrayed.
The corporate university also compromises the concept of academic leadership. Deans who reached their leadership positions by virtue of distinguished contributions to their disciplines have in places been replaced with fundraisers and academic managers, who are forced to demonstrate their profitability or show how they can attract corporate sponsors. In medicine, those who succeed in academia are likely to be key opinion leaders (KOLs in marketing parlance), whose careers can be advanced through the opportunities provided by industry. Potential KOLs are selected based on a complex array of profiling activities carried out by companies, for example, physicians are selected based on their influence on prescribing habits of other physicians.7 KOLs are sought out by industry for this influence and for the prestige that their university affiliation brings to the branding of the company’s products. As well paid members of pharmaceutical advisory boards and speakers’ bureaus, KOLs present results of industry trials at medical conferences and in continuing medical education. Instead of acting as independent, disinterested scientists and critically evaluating a drug’s performance, they become what marketing executives refer to as “product champions.”
Ironically, industry sponsored KOLs appear to enjoy many of the advantages of academic freedom, supported as they are by their universities, the industry, and journal editors for expressing their views, even when those views are incongruent with the real evidence. While universities fail to correct misrepresentations of the science from such collaborations, critics of industry face rejections from journals, legal threats, and the potential destruction of their careers.8 This uneven playing field is exactly what concerned Popper when he wrote about suppression and control of the means of science communication.9 The preservation of institutions designed to further scientific objectivity and impartiality (i.e., public laboratories, independent scientific periodicals and congresses) is entirely at the mercy of political and commercial power; vested interest will always override the rationality of evidence.10
Regulators receive funding from industry and use industry funded and performed trials to approve drugs, without in most cases seeing the raw data. What confidence do we have in a system in which drug companies are permitted to “mark their own homework” rather than having their products tested by independent experts as part of a public regulatory system? Unconcerned governments and captured regulators are unlikely to initiate necessary change to remove research from industry altogether and clean up publishing models that depend on reprint revenue, advertising, and sponsorship revenue.
Our proposals for reforms include: liberation of regulators from drug company funding; taxation imposed on pharmaceutical companies to allow public funding of independent trials; and, perhaps most importantly, anonymised individual patient level trial data posted, along with study protocols, on suitably accessible websites so that third parties, self-nominated or commissioned by health technology agencies, could rigorously evaluate the methodology and trial results. With the necessary changes to trial consent forms, participants could require trialists to make the data freely available. The open and transparent publication of data are in keeping with our moral obligation to trial participants—real people who have been involved in risky treatment and have a right to expect that the results of their participation will be used in keeping with principles of scientific rigour. Industry concerns about privacy and intellectual property rights should not hold sway.
THE JAPANESE JOURNAL OF ANTIBIOTICS 74―1 61( 61 ) http://jja-contents.wdc-jp.com/pdf/JJ…
News
Common Medication Could Save Half a Million Lives Each Year – So Why Isn’t It?
A recent study conducted by scientists at the University of Southern California sheds light on the reasons why children are not receiving an affordable and effective diarrhea treatment. Medical professionals in developing nations are [...]
X Marks the Spot: AI’s Treasure Maps Lead to Early Disease Detection
Medical diagnostics expert, doctor’s assistant, and cartographer are all fair titles for an artificial intelligence model developed by researchers at the Beckman Institute for Advanced Science and Technology. Their new model accurately identifies tumors [...]
Scientists Discover Method To Identify Alzheimer’s Disease Before It Progresses to Dementia
Researchers at Aarhus University have discovered a method to identify Alzheimer’s disease before it progresses to dementia, potentially opening up new avenues for treatment. A groundbreaking study could pave the way for early detection [...]
Startling Discovery: COVID-19 Virus Can Stay in the Body More Than a Year After Infection
The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended, according to new research from UC San Francisco that offers potential [...]
New bioengineered protein design shows promise in fighting COVID-19
In the wake of the COVID-19 pandemic, scientists have been racing to develop effective treatments and preventatives against the virus. A recent scientific breakthrough has emerged from the work of researchers aiming to combat [...]
Sugar-coated gold nanoparticles can quickly eliminate bacterial infections, no antibiotics required
If left to their own devices, bacteria on our teeth or wounded skin can encase themselves in a slimy scaffolding, turning into what is called biofilm. These bacteria wreak havoc on our tissue and, [...]
Liquid Lightning: Nanotechnology Unlocks New Energy
EPFL researchers have discovered that nanoscale devices harnessing the hydroelectric effect can harvest electricity from the evaporation of fluids with higher ion concentrations than purified water, revealing a vast untapped energy potential. Evaporation is a natural [...]
Unmasking the Illusion: AI-Generated Faces Challenge Perceptions
Research shows survey participants duped by AI-generated images nearly 40 percent of the time. If you recently had trouble figuring out if an image of a person is real or generated through artificial intelligence [...]
New Discovery Reveals How Cells Defend Themselves During Stressful Situations
Stress granules play a crucial role in the stress response, arising from the aggregation of non-translating mRNAs and proteins. Although significant knowledge exists about stress granules, the mechanisms behind their mRNA localization remain partially [...]
Scientists use a new type of nanoparticle that can both deliver vaccines and act as an adjuvant
Many vaccines, including vaccines for hepatitis B and whooping cough, consist of fragments of viral or bacterial proteins. These vaccines often include other molecules called adjuvants, which help to boost the immune system's response [...]
Not Science Fiction: How Optical Neural Networks Are Revolutionizing AI
A novel architecture for optical neural networks utilizes wavefront shaping to precisely manipulate the travel of ultrashort pulses through multimode fibers, enabling nonlinear optical computation. Present-day artificial intelligence systems rely on billions of adjustable [...]
Turning skin cells into limb cells sets the stage for regenerative therapy
In a collaborative study, researchers from Kyushu University and Harvard Medical School have identified proteins that can turn or “reprogram” fibroblasts — the most commonly found cells in skin and connective tissue — into [...]
AI reveals prostate cancer is not just one disease
Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer, which could revolutionise how the disease is diagnosed and treated in the future. A Cancer Research UK-funded study, published in Cell Genomics, has revealed [...]
New Study Finds That Persistent COVID-19 Infections Are Surprisingly Common
Recent research conducted by the University of Oxford has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more. The findings have been published in the journal Nature. [...]
Innovative nanosheet method revolutionizes brain imaging for multi-scale and long-term studies
The human brain has billions of neurons. Working together, they enable higher-order brain functions such as cognition and complex behaviors. To study these higher-order brain functions, it is important to understand how neural activity [...]
Scientists Have Discovered a Potential Universal Antivenom
Scientists at Scripps Research identified antibodies that protect against a host of lethal snake venoms. Scripps Research scientists have developed an antibody that can block the effects of lethal toxins in the venoms of [...]